Health System

Patients with atopic dermatitis who achieved rapid changes in skin pain severity with the Janus kinase inhibitor baricitinib were associated with clinically significant improvement in Dermatology Life Quality Index scores.

The Biden administration plans to expand Affordable Care Act (ACA) coverage to more families; new guidelines jointly announced by cardiology organizations for the treatment and prevention of heart failure; World Health Organization estimates that 99% of people worldwide are exposed to poor air quality.

Two abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting explored the health-related quality of life (QOL) and mental health impact of psoriasis disease burden by severity and affected body region.

Later school start times are being considered to address youth mental health crises; states are taking action to enact legislation on opioid addiction and fentanyl-related deaths; Unilever recalls 2 Suave aerosol antiperspirant products due to a potential carcinogen.

Many oncologists oppose white bagging because they prefer to be able to adjust doses during a visit based on lab reports taken that day.

A significantly greater proportion of patients with chronic rhinosinusitis with nasal polyps reported symptom-free days for at least 1 symptom when treated with dupilumab vs placebo in the 28 days preceding 24-week and 52-week analysis intervals.

Only half of pediatric patients with atopic dermatitis who fit the criteria of having severe disease were identified as such by managing physicians.

Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.

Implementing changes in a health system to promote biosimilar adoption is not easy, but by implementing a program, there could be substantial savings.

The clinical effectiveness of chimeric antigen receptor (CAR) T-cell therapies adds a new weapon in the arsenal to treat patients with relapsed and refractory disease; however, they come with access, logistical, and reimbursement challenges that make it difficult to treat all the patients who could benefit.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Democrats and Republicans are near agreement on a $10 billion COVID-19 funding package; scientists perform the first complete, gapless sequence of a human genome; more than a third of high school students reported they experienced poor mental health during the pandemic.

Orly Vardeny, PharmD, MS, core investigator, Center for Care Delivery and Outcomes Research, and associate professor of Medicine, University of Minnesota Medical School, discusses key barriers to access of novel therapies and what sessions she’s looking forward to during the American College of Cardiology's (ACC) 71st Annual Scientific Session.

This subanalysis of participant data from the OPEN project investigated relationships between glycemic levels and insulin requirements among women with type 1 diabetes and phases of their menstrual cycle.

Younger and older patients with noneosinophilic chronic rhinosinusitis (CRS) with nasal polyps showed significant differences in preoperative blood eosinophil levels and postoperative modified Lund-Kennedy scores.

Although the medication therapy management program in Tennessee's Medicaid population did not reduce costs, some adherence to medication improved and emergency department visits improved.

Findings of 2 abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting showed that ruxolitinib cream (​​Opzelura) demonstrated significant improvement vs vehicle in patients with atopic dermatitis of Black race and across anatomic regions.

A new FAIR Health white paper containing the fifth annual edition of FH Healthcare Indicators and FH Medical Price Index was released, showing a dramatic increase in telehealth utilization from 2019 to 2020.

Longer drug survival was associated with interleukin-17 (IL-17) inhibitors vs tumor necrosis factor (TNF) inhibitors in the treatment of psoriasis and psoriatic arthritis, but persistence rates for first-line biologics overall remained low.

UnitedHealth Group will buy LHC Group for $5.4 billion as part of its home health care expansion plan; the FDA approved a second COVID-19 booster dose for adults aged 50 and older; a study found differing patterns of clinic and emergency department acute-care use between White, Black, and Latino or Hispanic children with asthma.

A Monday session at the 2022 American Academy of Dermatology Annual Meeting discussed strategies for risk stratification and therapeutic management of nonmelanoma skin cancers.

Clinical trial recruitment and management strategies for diverse populations are among the challenges that affect dermatology care quality and access, according to panelists at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

Panelists reviewed the latest advancements in clinical testing for melanoma, targeted therapy implications, and strategies for patient selection at a session on genetic and molecular testing at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.

Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.

Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, explains factors inhibiting uptake of next-generation sequencing testing among patients with lung cancer.

The FDA accepts an application for a drug to treat amyotriphic lateral sclerosis (ALS) for review; vaccines have been found to reduce people’s risk for developing long COVID-19; COTA announces Miruna Sasu, PhD, as its new president and CEO.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on considerations for dermatologists in seeking payer coverage of novel, expensive therapies for atopic dermatitis.